Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

Bibliography

• WALLACE ME, SMYTH MJ: The role of natural killer cells in tumour control-effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. (2005) 27(1):49-64.
   PubMed Web of Science ®Google Scholar
• WU J, LANIER LL: Natural killer cells and cancer. Adv. Cancer Res. (2003) 90:127-156.
   PubMed Web of Science ®Google Scholar
• RAULET DH: Natural killer cells. In: Fundamental Immunology. Paul WE (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2003):365-391.
   Google Scholar
• DI SANTO JP: Natural killer cell developmental pathways: a question of balance. Annu. Rev. Immunol. (2006) 24:257-286.
   PubMed Web of Science ®Google Scholar
• CHAN CW, CRAFTON E, FAN HN et al.: Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. (2006) 12(2):207-213.
   PubMed Web of Science ®Google Scholar
• TAIEB J, CHAPUT N, MENARD C et al.: A novel dendritic cell subset involved in tumour immunosurveillance. Nat. Med. (2006) 12(2):214-219.
   PubMed Web of Science ®Google Scholar
• LOPEZ-BOTET M, PEREZ-VILLAR JJ, CARRETERO M et al.: Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol. Rev. (1997) 155:165-174.
   PubMed Web of Science ®Google Scholar
• MAK TW, SAUNDERS M: Bridging innate and adaptive immunity: NK, γδ T, and NKT cells. In: The Immune Response: Basic and Clinical Principles. Mak TW, Saunders M (Eds), Academic Press, San Diego, CA, USA (2005).
   Google Scholar
• TAKEDA K, HAYAKAWA Y, SMYTH MJ et al.: Involvement of tumour necrosis factor-related apoptosis-inducing ligand in surveillance of tumour metastasis by liver natural killer cells. Nat. Med. (2001) 7(1):94-100.
   PubMed Web of Science ®Google Scholar
• CRETNEY E, TAKEDA K, YAGITA H et al.: Increased susceptibility to tumour initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. (2002) 168(3):1356-1361.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, TAKEDA K, HAYAKAWA Y et al.: Nature’s TRAIL-on a path to cancer immunotherapy. Immunity (2003) 18(1):1-6.
   PubMed Web of Science ®Google Scholar
• SCREPANTI V, WALLIN RP, LJUNGGREN HG, GRANDIEN A: A central role for death receptor-mediated apoptosis in the rejection of tumours by NK cells. J. Immunol. (2001) 167(4):2068-2073.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA WM: Natural killer cells. In: Fundamental Immunology. Paul WE (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (1999):575-603.
   Google Scholar
• RODA JM, PARIHAR R, LEHMAN A et al.: Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. (2006) 177(1):120-129.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, HAYAKAWA Y, TAKEDA K, YAGITA H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer (2002) 2(11):850-861.
   PubMed Web of Science ®Google Scholar
• DUNN GP, KOEBEL CM, SCHREIBER RD: Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. (2006) 6(11):836-848.
   PubMed Web of Science ®Google Scholar
• KARRE K, LJUNGGREN HG, PIONTEK G, KIESSLING R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 319(6055):675-678.
   PubMed Web of Science ®Google Scholar
• MANDELBOIM O, LIEBERMAN N, LEV M et al.: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 409(6823):1055-1060.
   PubMed Web of Science ®Google Scholar
• LANIER LL: NK cell recognition. Annu. Rev. Immunol. (2005) 23:225-274.
   PubMed Web of Science ®Google Scholar
• LEE N, LLANO M, CARRETERO M et al.: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA (1998) 95(9):5199-5204.
   PubMed Web of Science ®Google Scholar
• ITO M, MARUYAMA T, SAITO N et al.: Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J. Exp. Med. (2006) 203(2):289-295.
   PubMed Web of Science ®Google Scholar
• ANFOSSI N, ANDRE P, GUIA S et al.: Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 25(2):331-342.
   PubMed Web of Science ®Google Scholar
• BOTTINO C, MORETTA L, MORETTA A: NK cell activating receptors and tumour recognition in humans. Curr. Top. Microbiol. Immunol. (2006) 298:175-182.
   PubMed Web of Science ®Google Scholar
• RAULET DH: Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. (2003) 3(10):781-790.
   PubMed Web of Science ®Google Scholar
• FARAG SS, CALIGIURI MA: Human natural killer cell development and biology. Blood Rev. (2006) 20(3):123-137.
   PubMed Web of Science ®Google Scholar
• ARNON TI, LEV M, KATZ G et al.: Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. (2001) 31(9):2680-2689.
   PubMed Web of Science ®Google Scholar
• ARAMBURU J, BALBOA MA, RODRIGUEZ A et al.: Stimulation of IL-2-activated natural killer cells through the Kp43 surface antigen upregulates TNF-alpha production involving the LFA-1 integrin. J. Immunol. (1993) 151(7):3420-3429.
   PubMed Web of Science ®Google Scholar
• OSMAN MS, BURSHTYN DN, KANE KP: Activating Ly-49 receptors regulate LFA-1-mediated adhesion by NK cells. J. Immunol. (2007) 178(3):1261-1267.
   PubMed Web of Science ®Google Scholar
• BARBER DF, FAURE M, LONG EO: LFA-1 contributes an early signal for NK cell cytotoxicity. J. Immunol. (2004) 173(6):3653-3659.
   PubMed Web of Science ®Google Scholar
• MELERO I, BALBOA MA, ALONSO JL et al.: Signalling through the LFA-1 leucocyte integrin actively regulates intercellular adhesion and tumour necrosis factor-alpha production in natural killer cells. Eur. J. Immunol. (1993) 23(8):1859-1865.
   PubMed Web of Science ®Google Scholar
• KELLY JM, DARCY PK, MARKBY JL et al.: Induction of tumour-specific T cell memory by NK cell-mediated tumour rejection. Nat. Immunol. (2002) 3(1):83-90.
   PubMed Web of Science ®Google Scholar
• KELLY JM, TAKEDA K, DARCY PK, YAGITA H, SMYTH MJ: A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumour-expressing CD80 in vivo. J. Immunol. (2002) 168(9):4472-4479.
   PubMed Web of Science ®Google Scholar
• LEIBSON PJ: Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity (1997) 6(6):655-661.
   PubMed Web of Science ®Google Scholar
• KALINSKI P, MAILLIARD RB, GIERMASZ A et al.: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. (2005) 5(10):1303-1315.
   PubMed Web of Science ®Google Scholar
• DEGLI-ESPOSTI MA, SMYTH MJ: Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. (2005) 5(2):112-124.
   PubMed Web of Science ®Google Scholar
• FERLAZZO G, PACK M, THOMAS D et al.: Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA (2004) 101(47):16606-16611.
   PubMed Web of Science ®Google Scholar
• GRANUCCI F, ZANONI I, PAVELKA N et al.: A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. (2004) 200(3):287-295.
   PubMed Web of Science ®Google Scholar
• BORG C, JALIL A, LADERACH D et al.: NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 104(10):3267-3275.
   PubMed Web of Science ®Google Scholar
• TERME M, TOMASELLO E, MARUYAMA K et al.: IL-4 confers NK stimulatory capacity to murine dendritic cells: a signalling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J. Immunol. (2004) 172(10):5957-5966.
   PubMed Web of Science ®Google Scholar
• SEMINO C, ANGELINI G, POGGI A, RUBARTELLI A: NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 106(2):609-616.
   PubMed Web of Science ®Google Scholar
• PICCIOLI D, SBRANA S, MELANDRI E, VALIANTE NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. (2002) 195(3):335-341.
   PubMed Web of Science ®Google Scholar
• FERLAZZO G, TSANG ML, MORETTA L et al.: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. (2002) 195(3):343-351.
   PubMed Web of Science ®Google Scholar
• GEROSA F, BALDANI-GUERRA B, NISII C et al.: Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. (2002) 195(3):327-333.
   PubMed Web of Science ®Google Scholar
• POGGI A, CAROSIO R, SPAGGIARI GM et al.: NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J. Immunol. (2002) 168(1):95-101.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA Y, SCREPANTI V, YAGITA H et al.: NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. (2004) 172(1):123-129.
   PubMed Web of Science ®Google Scholar
• DELLA CHIESA M, VITALE M, CARLOMAGNO S et al.: The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. (2003) 33(6):1657-1666.
   PubMed Web of Science ®Google Scholar
• PAN PY, GU P, LI Q et al.: Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J. Immunol. (2004) 172(8):4779-4789.
   PubMed Web of Science ®Google Scholar
• MOCIKAT R, BRAUMULLER H, GUMY A et al.: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity (2003) 19(4):561-569.
   PubMed Web of Science ®Google Scholar
• MARTIN-FONTECHA A, THOMSEN LL, BRETT S et al.: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. (2004) 5(12):1260-1265.
   PubMed Web of Science ®Google Scholar
• STRBO N, OIZUMI S, SOTOSEK-TOKMADZIC V, PODACK ER: Perforin is required for innate and adaptive immunity induced by heat-shock protein gp96. Immunity (2003) 18(3):381-390.
   PubMed Web of Science ®Google Scholar
• WESTWOOD JA, KELLY JM, TANNER JE et al.: Cutting edge: novel priming of tumour-specific immunity by NKG2D-triggered NK cell-mediated tumour rejection and Th1-independent CD4+ T cell pathway. J. Immunol. (2004) 172(2):757-761.
   PubMed Web of Science ®Google Scholar
• GROH V, RHINEHART R, SECRIST H et al.: Broad tumour-associated expression and recognition by tumour-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA (1999) 96(12):6879-6884.
   PubMed Web of Science ®Google Scholar
• DIEFENBACH A, JAMIESON AM, LIU SD, SHASTRI N, RAULET DH: Ligands for the murine NKG2D receptor: expression by tumour cells and activation of NK cells and macrophages. Nat. Immunol. (2000) 1(2):119-126.
   PubMed Web of Science ®Google Scholar
• UPSHAW JL, LEIBSON PJ: NKG2D-mediated activation of cytotoxic lymphocytes: unique signalling pathways and distinct functional outcomes. Semin. Immunol. (2006) 18(3):167-175.
   PubMed Web of Science ®Google Scholar
• REGUNATHAN J, CHEN Y, WANG D, MALARKANNAN S: NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood (2005) 105(1):233-240.
   PubMed Web of Science ®Google Scholar
• CARBONE E, NERI P, MESURACA M et al.: HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2005) 105(1):251-258.
   PubMed Web of Science ®Google Scholar
• DIEFENBACH A, JENSEN ER, JAMIESON AM, RAULET DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 413(6852):165-171.
   PubMed Web of Science ®Google Scholar
• CERWENKA A, BARON JL, LANIER LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumour in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(20):11521-11526.
   PubMed Web of Science ®Google Scholar
• DIEFENBACH A, HSIA JK, HSIUNG MY, RAULET DH: A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumour immunity. Eur. J. Immunol. (2003) 33(2):381-391.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, SWANN J, CRETNEY E et al.: NKG2D function protects the host from tumour initiation. J. Exp. Med. (2005) 202(5):583-588.
   PubMed Web of Science ®Google Scholar
• CONEJO-GARCIA JR, BENENCIA F, COURREGES MC et al.: Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumour T cells. Cancer Res. (2004) 64(6):2175-2182.
   PubMed Web of Science ®Google Scholar
• GASSER S, RAULET DH: The DNA damage response arouses the immune system. Cancer Res. (2006) 66(8):3959-3962.
   PubMed Web of Science ®Google Scholar
• GIRARDI M, OPPENHEIM DE, STEELE CR et al.: Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294(5542):605-609.
   PubMed Web of Science ®Google Scholar
• GASSER S, ORSULIC S, BROWN EJ, RAULET DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 436(7054):1186-1190.
   PubMed Web of Science ®Google Scholar
• ROUTES JM, RYAN S, MORRIS K et al.: Adenovirus serotype 5 E1A sensitizes tumour cells to NKG2D-dependent NK cell lysis and tumour rejection. J. Exp. Med. (2005) 202(11):1477-1482.
   PubMed Web of Science ®Google Scholar
• GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature (2002) 419(6908):734-738.
   PubMed Web of Science ®Google Scholar
• SALIH HR, RAMMENSEE HG, STEINLE A: Cutting edge: downregulation of MICA on human tumours by proteolytic shedding. J. Immunol. (2002) 169(8):4098-4102.
   PubMed Web of Science ®Google Scholar
• WALDHAUER I, STEINLE A: Proteolytic release of soluble UL16-binding protein 2 from tumour cells. Cancer Res. (2006) 66(5):2520-2526.
   PubMed Web of Science ®Google Scholar
• OGASAWARA K, HAMERMAN JA, HSIN H et al.: Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 18(1):41-51.
   PubMed Web of Science ®Google Scholar
• OPPENHEIM DE, ROBERTS SJ, CLARKE SL et al.: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumour immunosurveillance. Nat. Immunol. (2005) 6(9):928-937.
   PubMed Web of Science ®Google Scholar
• COUDERT JD, ZIMMER J, TOMASELLO E et al.: Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumour cells. Blood (2005) 106(5):1711-1717.
   PubMed Web of Science ®Google Scholar
• GROH V, BRUHL A, EL-GABALAWY H, NELSON JL, SPIES T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2003) 100(16):9452-9457.
   PubMed Web of Science ®Google Scholar
• GROH V, SMYTHE K, DAI Z, SPIES T: Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumour immunity. Nat. Immunol. (2006) 7(7):755-762.
   PubMed Web of Science ®Google Scholar
• KRIEGESKORTE AK, GEBHARDT FE, PORCELLINI S et al.: NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc. Natl. Acad. Sci. USA (2005) 102(33):11805-11810.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA Y, SMYTH MJ: NKG2D and cytotoxic effector function in tumour immune surveillance. Semin. Immunol. (2006) 18(3):176-185.
   PubMed Web of Science ®Google Scholar
• WHITESIDE TL, HERBERMAN RB: Role of human natural killer cells in health and disease. Clin. Diagn. Lab. Immunol. (1994) 1(2):125-133.
   PubMedGoogle Scholar
• MARGOLIN KA: Interleukin-2 in the treatment of renal cancer. Semin. Oncol. (2000) 27(2):194-203.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, ATTIA P, STEINBERG SM, WHITE DE, ROSENBERG SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. (2001) 19(15):3477-3482.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, MUUL LM et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. (1987) 316(15):889-897.
   PubMed Web of Science ®Google Scholar
• BUZIO C, ANDRULLI S, SANTI R et al.: Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer (2001) 92(9):2286-2296.
   PubMed Web of Science ®Google Scholar
• SILLA LM, WHITESIDE TL, BALL ED: The role of natural killer cells in the treatment of chronic myeloid leukaemia. J. Hematother. (1995) 4(4):269-279.
   PubMedGoogle Scholar
• HARTMANN F, RENNER C, JUNG W et al.: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin’s disease: role of infusion schedule and costimulation with cytokines. Clin. Cancer Res. (2001) 7(7):1873-1881.
   PubMed Web of Science ®Google Scholar
• YASUMURA S, LIN WC, HIRABAYASHI H et al.: Immunotherapy of liver metastases of human gastric carcinoma with IL-2-activated natural killer cells. Cancer Res. (1994) 54(14):3808-3816.
   PubMed Web of Science ®Google Scholar
• RUGGERI L, CAPANNI M, URBANI E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-2100.
   PubMed Web of Science ®Google Scholar
• SHLOMCHIK WD, COUZENS MS, TANG CB et al.: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 285(5426):412-415.
   PubMed Web of Science ®Google Scholar
• DAVIES SM, RUGGIERI L, DEFOR T et al.: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 100(10):3825-3827.
   PubMed Web of Science ®Google Scholar
• GIEBEL S, LOCATELLI F, LAMPARELLI T et al.: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102(3):814-819.
   PubMed Web of Science ®Google Scholar
• MILLER JS, SOIGNIER Y, PANOSKALTSIS-MORTARI A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-3057.
   PubMed Web of Science ®Google Scholar
• MELERO I, ARINA A, MURILLO O et al.: Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin. Cancer Res. (2006) 12(8):2385-2389.
   PubMed Web of Science ®Google Scholar
• MELERO I, HERVAS-STUBBS S, GLENNIE M, PARDOLL DM, CHEN L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer. (2007) 7(2):95-106.
   PubMed Web of Science ®Google Scholar
• MURILLO O, ARINA A, TIRAPU I et al.: Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin. Cancer Res. (2003) 9(15):5454-5464.
   PubMed Web of Science ®Google Scholar
• GODFREY DI, KRONENBERG M: Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. (2004) 114(10):1379-1388.
   PubMed Web of Science ®Google Scholar
• TERABE M, PARK JM, BERZOFSKY JA: Role of IL-13 in regulation of antitumour immunity and tumour growth. Cancer Immunol. Immunother. (2004) 53(2):79-85.
   PubMed Web of Science ®Google Scholar
• BENDELAC A, SAVAGE PB, TEYTON L: The biology of NKT cells. Annu. Rev. Immunol. (2006) 6:6.
   Google Scholar
• SENTMAN CL, BARBER MA, BARBER A, ZHANG T: NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res. (2006) 95:249-292.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, CROWE NY, GODFREY DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. (2001) 13(4):459-463.
   PubMed Web of Science ®Google Scholar
• ARGOV S, COCHRAN AJ, KARRE K, KLEIN GO, KLEIN G: Incidence and type of tumours induced in C57BL bg/bg mice and +/bg littermates by oral administration of DMBA. Int. J. Cancer (1981) 28(6):739-746.
   PubMed Web of Science ®Google Scholar
• GALLO-HENDRIKX E, COPPS J, PERCY D, CROY BA, WILDEMAN AG: Enhancement of pancreatic tumour metastasis in transgenic immunodeficient mice. Oncogene (1994) 9(10):2983-2990.
   PubMed Web of Science ®Google Scholar
• SHULTZ LD, SCHWEITZER PA, CHRISTIANSON SW et al.: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. (1995) 154(1):180-191.
   PubMed Web of Science ®Google Scholar
• KIM S, IIZUKA K, AGUILA HL, WEISSMAN IL, YOKOYAMA WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA (2000) 97(6):2731-2736.
   PubMed Web of Science ®Google Scholar
• VAN DEN BROEK ME, KAGI D, OSSENDORP F et al.: Decreased tumour surveillance in perforin-deficient mice. J. Exp. Med. (1996) 184(5):1781-1790.
   PubMed Web of Science ®Google Scholar
• KAPLAN DH, SHANKARAN V, DIGHE AS et al.: Demonstration of an interferon gamma-dependent tumour surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA (1998) 95(13):7556-7561.
   PubMed Web of Science ®Google Scholar
• OWEN-SCHAUB LB, VAN GOLEN KL, HILL LL, PRICE JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. (1998) 188(9):1717-1723.
   PubMed Web of Science ®Google Scholar
• STREET SE, CRETNEY E, SMYTH MJ: Perforin and interferon-gamma activities independently control tumour initiation, growth, and metastasis. Blood (2001) 97(1):192-197.
   PubMed Web of Science ®Google Scholar
• SHANKARAN V, IKEDA H, BRUCE AT et al.: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-1111.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, CRETNEY E, TAKEDA K et al.: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumour metastasis. J. Exp. Med. (2001) 193(6):661-670.
   PubMed Web of Science ®Google Scholar
• LJUNGGREN HG, KARRE K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. (1985) 162(6):1745-1759.
   PubMed Web of Science ®Google Scholar
• GAO JX, LIU X, WEN J et al.: Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumour cells. Blood (2003) 102(13):4456-4463.
   PubMed Web of Science ®Google Scholar
• BRADLEY M, ZEYTUN A, RAFI-JANAJREH A, NAGARKATTI PS, NAGARKATTI M: Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumour cells. Blood (1998) 92(11):4248-4255.
   PubMed Web of Science ®Google Scholar
• KARP SE, FARBER A, SALO JC et al.: Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumour inhibition by IL-2 but not tumour necrosis factor. J. Immunol. (1993) 150(3):896-908.
   PubMed Web of Science ®Google Scholar
• ORTALDO JR, WINKLER-PICKETT RT, BERE EW JR et al.: In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J. Immunol. (2005) 175(2):693-699.
   PubMed Web of Science ®Google Scholar
• DIVINO CM, CHEN SH, YANG W et al.: Antitumour immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res. Treat. (2000) 60(2):129-134.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-CALVILLO M, DUARTE M, TIRAPU I et al.: Upregulation of natural killer cells functions underlies the efficacy of intratumourally injected dendritic cells engineered to produce interleukin-12. Exp. Hematol. (2002) 30(3):195-204.
   PubMed Web of Science ®Google Scholar
• CHAPOVAL AI, FULLER JA, KREMLEV SG, KAMDAR SJ, EVANS R: Combination chemotherapy and IL-15 administration induce permanent tumour regression in a mouse lung tumour model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. (1998) 161(12):6977-6984.
   PubMed Web of Science ®Google Scholar
• MEAZZA R, LOLLINI PL, NANNI P et al.: Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer (2000) 87(4):574-581.
   PubMed Web of Science ®Google Scholar
• VERA M, RAZQUIN N, PRIETO J et al.: Intratumoural injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol. Ther. (2005) 12(5):950-959.
   PubMed Web of Science ®Google Scholar
• WANG G, TSCHOI M, SPOLSKI R et al.: In vivo antitumour activity of IL-21 mediated by natural killer cells. Cancer Res. (2003) 63(24):9016-9022.
   PubMed Web of Science ®Google Scholar
• TAKAKI R, HAYAKAWA Y, NELSON A et al.: IL-21 enhances tumour rejection through a NKG2D-dependent mechanism. J. Immunol. (2005) 175(4):2167-2173.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, WALLACE ME, NUTT SL et al.: Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. (2005) 201(12):1973-1985.
   PubMed Web of Science ®Google Scholar
• SMYTH MJ, SWANN J, KELLY JM et al.: NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. (2004) 200(10):1325-1335.
   PubMed Web of Science ®Google Scholar
• BRAUN SE, CHEN K, FOSTER RG et al.: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumour rejection of murine breast cancer cells through NK cells. J. Immunol. (2000) 164(8):4025-4031.
   PubMed Web of Science ®Google Scholar
• MELERO I, JOHNSTON JV, SHUFFORD WW, MITTLER RS, CHEN L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumour immunity elicited by anti4-1BB monoclonal antibodies. Cell. Immunol. (1998) 190(2):167-172.
   PubMed Web of Science ®Google Scholar
• WILCOX RA, TAMADA K, STROME SE, CHEN L: Signalling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. (2002) 169(8):4230-4236.
   PubMed Web of Science ®Google Scholar
• ESPLUGUES E, VEGA-RAMOS J, CARTOIXA D et al.: Induction of tumour NK-cell immunity by anti-CD69 antibody therapy. Blood (2005) 105(11):4399-4406.
   PubMed Web of Science ®Google Scholar